| Fan, Jia |
NCT05660213: Effect and Safety of Huaier Granules Combined With Targeted Drugs and Anti-PD-(L)1 Antibody Compared With Targeted Drugs Combined With Anti-PD-(L)1 Antibody in First Line Treatment of Unresectable Hepatocellular Carcinoma(uHCC) |
|
|
| Not yet recruiting | 4 | 600 | NA | Huaier granule, Atezolizumab + Bevacizumab, Camrelizumab+Apatinib, Sintilimab+Bevacizumab | Fudan University, LinkDoc Technology (Beijing) Co. Ltd., Huazhong University of Science and Technology | Unresectable Hepatocellular Carcinoma | 09/25 | 01/27 | | |
NCT04720716: A Study to Compare the Effectiveness and Safety of IBI310 Combined With Sintilimab Versus Sorafenib in the First-line Treatment of Advanced HCC |
|
|
| Recruiting | 3 | 490 | RoW | IBI310, Sintilimab, Sorafenib | Innovent Biologics (Suzhou) Co. Ltd. | Hepatocellular Carcinoma | 12/23 | 12/23 | | |
ALTN-AK105-III-02, NCT04344158: A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC) |
|
|
| Active, not recruiting | 3 | 648 | RoW | AK105 Injection, Anlotinib Hydrochloride Capsules, Sorafenib Tosylate Tablets | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Hepatocellular Carcinoma (HCC) | 12/26 | 12/26 | | |
NCT05320692: A Study of TACE Combined With Camrelizumab Plus Rivoceranib (Apatinib) in Patients With Incurable Hepatocellular Carcinoma |
|
|
| Recruiting | 3 | 360 | RoW | TACE+Camrelizumab+Apatinib mesylate, TACE | Jiangsu HengRui Medicine Co., Ltd. | Hepatocellular Carcinoma | 07/24 | 07/26 | | |
| Active, not recruiting | 3 | 908 | Europe, Canada, Japan, US, RoW | Durvalumab, IMFINZI, Bevacizumab, AVASTIN, Placebo | AstraZeneca, AstraZeneca AB | Hepatocellular Carcinoma | 05/26 | 05/27 | | |
|
|
AK104-306, NCT05489289: A Phase III Study of AK104 as Adjuvant Therapy in HCC With High Risk of Recurrence After Curative Resection |
|
|
| Not yet recruiting | 3 | 405 | RoW | AK104, placebo | Akeso | Hepatocellular Carcinoma | 01/25 | 11/26 | | |
NCT04669496: Phase II-III Clinical Trial of PD1 Antibody (Toripalimab), Lenvatinib and GEMOX Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors |
|
|
| Recruiting | 2/3 | 178 | RoW | Neoadjuvant treatment | Shanghai Zhongshan Hospital, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 6th People's Hospital, Shanghai Public Health Clinical Center, RenJi Hospital, Shenzhen University General Hospital | Intrahepatic Cholangiocarcinoma, PD1 Antibody, Lenvatinib, Gemox Chemotherapy | 12/22 | 12/24 | | |
DUBHE-H-308, NCT05976568: A Study of QL1706 in Combination With Bevacizumab and/or Chemotherapy as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma |
|
|
| Not yet recruiting | 2/3 | 668 | RoW | QL1706, Bevacizumab, Oxaliplatin injection, Capecitabine, Sintilimab | Qilu Pharmaceutical Co., Ltd. | Hepatocellular Carcinoma | 09/27 | 09/27 | | |
NCT04506281: PD1 Antibody (Toripalimab), GEMOX and Lenvatinib Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors |
|
|
| Recruiting | 2 | 128 | RoW | neoadjuvant treatment | Shanghai Zhongshan Hospital, Xuhui Central Hospital, Shanghai, Minhang Hospital, Fudan University, Shanghai Jinshan Hospital, Shenzhen University General Hospital | Cholangiocarcinoma, Intrahepatic | 08/21 | 08/23 | | |
ZSAB-TOP, NCT05023109: GP Chemotherapy in Combination With Anti-PD-1 and Anti-TIGIT in Unresectable Advanced BTC |
|
|
| Active, not recruiting | 2 | 45 | RoW | GP+PD-1+Tight | Shanghai Zhongshan Hospital, Jining Medical University, Cancer Hospital of Guangxi Medical University | Biliary Tract Carcinoma | 01/23 | 12/24 | | |
NCT05190575: TST001 in Patients With CLDN18.2 Positive Previously Treated Advanced Biliary Tract Cancer |
|
|
| Completed | 2 | 8 | RoW | TST001 | Shanghai Zhongshan Hospital, Transcenta Holding Limited | Biliary Tract Neoplasms | 05/23 | 05/23 | | |
ZSAB-TransGOLP, NCT05156788: Tislelizumab（Anti PD-1), Lenvatinib and GEMOX Transformation in the Treatment of Potentially Resectable, Locally Advanced Biliary Tract Cancer |
|
|
| Active, not recruiting | 2 | 40 | RoW | PD-1+Lenvatinib+GEMOX | Shanghai Zhongshan Hospital | Biliary Tract Cancer, PD-1 Antibody, Gemox, Lenvatinib | 07/23 | 10/25 | | |
NCT04550624: Pembrolizumab in Combination With Lenvatinib in Patients With Advanced Biliary Tract Carcinoma |
|
|
| Recruiting | 2 | 40 | RoW | Pembrolizumab Injection [Keytruda], Keytruda, Lenvatinib Mesylate, Lenvima | Shanghai Jiahui International Hospital, Shanghai Zhongshan Hospital | Advanced Biliary Tract Carcinoma | 12/24 | 12/25 | | |
SHR-A1811-212, NCT06413745: Phase II Clinical Study of SHR-A1811 in Patients With HER2 Expression / Amplification of Locally Advanced Unresectable or Recurrent Metastatic Biliary Tract Cancer |
|
|
| Recruiting | 2 | 65 | RoW | SHR-A1811 | Jiangsu HengRui Medicine Co., Ltd. | HER2 Expression / Amplification in Patients With Biliary Tract Cancer | 09/25 | 09/25 | | |
NCT06349980: A Study to Explore the Reasonable Dosage and Evaluate the Efficacy, Safety and Tolerability of HLX10 and HLX04 with or Without HLX53 in Untreated, Locally Advanced or Metastatic Hepatocellular Carcinoma Patients. |
|
|
| Recruiting | 2 | 117 | RoW | HLX53 (1000mg), HLX53 (2000mg), HLX10, Serplulimab, HLX04, Bevacizumab, Placebo | Shanghai Henlius Biotech | Carcinoma, Hepatocellular | 02/27 | 02/27 | | |
NCT06620848: A Study of HRS-4642 Monotherapy or in Combination with Adebrelimab in the Treatment of Advanced Biliary Tract Tumors. |
|
|
| Not yet recruiting | 2 | 49 | RoW | HRS-4642 monotherapy, HRS-4642 and adebrelimab combination therapy | Shanghai Zhongshan Hospital | Biliary Tract Cancer | 12/26 | 06/27 | | |
FAITH, NCT06031480: Anlotinib and TQB2450 in Advanced Hepatocellular Carcinoma After Failure of Prior Immune Checkpoint Inhibitors |
|
|
| Not yet recruiting | 2 | 55 | RoW | Anlotinib and TQB2450 | Shanghai Zhongshan Hospital, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Hepatocellular Carcinoma | 10/25 | 12/25 | | |
NCT03867370: Toripalimab in Combination With Lenvatinib as Neoadjuvant Therapy in Resectable Hepatocellular Carcinoma |
|
|
| Terminated | 1/2 | 40 | RoW | Toripalimab (JS001 ), Toripalimab (JS001 ) Lenvatinib | Shanghai Junshi Bioscience Co., Ltd. | Hepatocellular Carcinoma | 08/23 | 08/23 | | |
NCT06378593: A Study of 3HP-2827 in Treatment of Unresectable or Metastatic Solid Tumors With FGFR2 Alterations |
|
|
| Recruiting | 1/2 | 130 | RoW | 3HP-2827 | 3H (Suzhou) Pharmaceuticals Co., Ltd. | Solid Tumors With FGFR2 Alterations, Adult | 06/28 | 06/28 | | |
NCT06111326: BC3402 in Combination With Durvalumab in Patients With Advanced Hepatocellular Carcinoma |
|
|
| Not yet recruiting | 1/2 | 83 | RoW | BC3402 injection, Durvalumab injection | Biocity Biopharmaceutics Co., Ltd. | Hepatocellular Carcinoma | 08/24 | 05/26 | | |
NCT06584071: A Study to Evaluate of PM8002 Combined With PM1009 in Patients With First-line HCC |
|
|
| Not yet recruiting | 1/2 | 140 | NA | PM8002, PM1009, atezolizumab, bevacizumab | Biotheus Inc. | HCC, Liver Cancer | 10/26 | 12/27 | | |
NCT05906524: KD6001 in Combination With Anti-PD-1 Antibody±Bevacizumab in Patients With Advanced HCC and Other Solid Tumors |
|
|
| Not yet recruiting | 1/2 | 85 | RoW | KD6001, Tislelizumab, Bevacizumab | Shanghai Kanda Biotechnology Co., Ltd. | Advanced HCC, Other Solid Tumors | 04/25 | 12/25 | | |
ZSAB-Calm, NCT05994001: Candonilimab in Combination With LM-302 for Claudin 18.2 Positive-advanced Biliary Tract Cancer After Failure of Standard of Chemotherapy and PD1/PD-L1 Antibody |
|
|
| Recruiting | 1/2 | 96 | RoW | cardonilizumab, PD1 and CTLA-4 bispecific antibody, LM-302, ClAUDIN 18.2-ADC | Shanghai Zhongshan Hospital | Biliary Tract Cancer, Candonilimab, Claudin 18.2 | 08/25 | 08/26 | | |
NCT05701553: Anti-PD-1/PD-L1 Antibodies Plus S-adenosyl-methionine Treatment in Patients With Advanced-Stage Hepatocellular Carcinoma |
|
|
| Recruiting | 1/2 | 20 | RoW | Anti-PD-1/PD-L1, S-Adenosyl-Methionine, SAM | Shanghai Zhongshan Hospital | Hepatocellular Carcinoma | 12/25 | 12/25 | | |
NCT05652920: Ori-C101Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of HCC |
|
|
| Recruiting | 1/2 | 105 | RoW | Ori-C101 | OriCell Therapeutics Co., Ltd. | Hepatocellular Carcinoma | 12/26 | 12/26 | | |
NCT06560827: CT011 Autologous CAR-T Cells in Patients With Hepatocellular Carcinoma at Risk of Recurrence After Surgical Resection |
|
|
| Recruiting | 1 | 30 | RoW | CT011 CAR-GPC3 T Cells Injection | CARsgen Therapeutics Co., Ltd., Shanghai Zhongshan Hospital | HCC | 12/26 | 06/27 | | |
BL0006-101, NCT06247657: A Phase I Study to Assess the Safety and Tolerability of BL0006 for Patients With Advanced Solid Tumours |
|
|
| Recruiting | 1 | 66 | RoW | BL0006 | Shanghai Best-Link Bioscience, LLC | Advanced Solid Tumor | 10/24 | 05/25 | | |
| Recruiting | 1 | 96 | US, RoW | GQ1001 | GeneQuantum Healthcare (Suzhou) Co., Ltd., Conjugate Light (Australia) Pty Ltd | HER2-positive Breast Cancer, HER2-positive Biliary Tract Cancer, HER2-Positive Salivary Gland Carcinomas, HER2-Positive Advanced Solid Tumor | 03/24 | 05/24 | | |
| Recruiting | 1 | 108 | RoW | IMM27M, IMM2510 | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | Advanced Solid Tumors, HCC | 01/26 | 01/26 | | |
NCT06757881: IL1RAP-targeting Chimeric Antigen Receptor T Cells in the Treatment of Relapsed/Refractory Hepatocellular Carcinoma |
|
|
| Not yet recruiting | 1 | 18 | RoW | Gene modified anti-IL1RAP Chimeric Antigen Receptor T Cells :1.0×10^8(First dose group), Gene modified anti-IL1RAP Chimeric Antigen Receptor T Cells :2.5×10^8(Second dose group), Gene modified anti-IL1RAP Chimeric Antigen Receptor T Cells :5.0×10^8（Third dose group） | Shanghai Zhongshan Hospital | HCC | 04/25 | 12/27 | | |
NCT03045731: An US Mathematical Model in Predicting Renal Transplant Rejection |
|
|
| Recruiting | N/A | 180 | RoW | | Shanghai Zhongshan Hospital | Kidney Transplantation | 09/22 | 12/22 | | |
| Not yet recruiting | N/A | 14026 | RoW | | Guangzhou Burning Rock Dx Co., Ltd. | Cancer | 10/22 | 03/23 | | |
| Recruiting | N/A | 14026 | RoW | Multi-cancer early detection test | Shanghai Zhongshan Hospital, Guangzhou Burning Rock Dx Co., Ltd. | Cancer | 12/22 | 03/23 | | |
TALENTop, NCT04649489: A Study to Evaluate Efficacy and Safety of Hepatic Resection for Liver Cancer with PVTT, HVTT or IVCTT After Initial Ate/Bev |
|
|
| Active, not recruiting | N/A | 501 | RoW | Atezolizumab, Bevacizumab, Surgery | Jia Fan | Venous Thrombosis | 08/27 | 03/28 | | |
| Zhou, Jian |
NCT05063071: Tenofovir Alafenamide for HBV Prophylaxis in Post Orthotopic Liver Transplant |
|
|
| Active, not recruiting | 4 | 150 | RoW | Tenofovir Alafenamide 25 MG | Fudan University | HBV, POST LIVER TRANSPLANT | 07/22 | 12/22 | | |
nAMD, NCT05461339: TAB014 Compared to Lucentis® in Patients with Neovascular Age-related Macular Degeneration |
|
|
| Active, not recruiting | 3 | 488 | RoW | TAB014 Monoclonal Antibody Injection, TAB014, Ranibizumab Injection [Lucentis], Lucentis | TOT Biopharm Co., Ltd., Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd. | Neovascular Age-related Macular Degeneration | 09/24 | 02/25 | | |
ALTN-AK105-III-02, NCT04344158: A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC) |
|
|
| Active, not recruiting | 3 | 648 | RoW | AK105 Injection, Anlotinib Hydrochloride Capsules, Sorafenib Tosylate Tablets | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Hepatocellular Carcinoma (HCC) | 12/26 | 12/26 | | |
NCT06507436: The Phase III Clinical Study of Herombopag for the Treatment of Thrombocytopenia in Chronic Liver Disease Patients Undergoing Elective Invasive Surgery |
|
|
| Recruiting | 3 | 101 | RoW | Herombopag tablets, Herombopag placebo tablets | Jiangsu HengRui Medicine Co., Ltd. | Thrombocytopenia in Chronic Liver Disease Patients Undergoing Elective Invasive Surgery | 08/25 | 09/25 | | |
NCT06591520: AK112 Combined With Chemotherapy Versus Durvalumab Combined With Chemotherapy in Advanced Biliary Tract Cancer |
|
|
| Not yet recruiting | 3 | 682 | RoW | AK112, Gemcitabine, Cisplatin, Durvalumab, Gemcitabine, Cisplatin | Akeso | Biliary Tract Cancer | 07/27 | 12/27 | | |
TQ05105-III-01, NCT06682169: Evaluation of Rovadicitinib Compared to the Protocol Selected by Researchers in Third Line and Subsequent Studies of Moderate to Severe Chronic Graft-versus-host Disease |
|
|
| Recruiting | 3 | 182 | RoW | Rovadicitinib, Imatinib, Methotrexate, Mycophenolate mofetil, Rituximab | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Graft-versus-host Disease | 10/29 | 12/30 | | |
ACHIEVE-3, NCT06045221: A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin |
|
|
| Active, not recruiting | 3 | 1576 | Japan, US, RoW | Orforglipron, LY3502970, Semaglutide | Eli Lilly and Company | Type 2 Diabetes | 09/25 | 09/25 | | |
NCT05342194: Toripalimab Plus Lenvatinib and Gemcitabine-based Chemotherapy in 1L Treatment of Advanced ICC: a Phase III Study |
|
|
| Not yet recruiting | 3 | 480 | RoW | Toripalimab, Tuoyi, Lenvatinib mesylate capsules, LENVIMA, Placebo IV, Toripalimab placebo, Oral placebo, Lenvatinib mesylate capsules placebo, Oxaliplatin for injection, Gemcitabine hydrochloride, Cisplatin | Shanghai Junshi Bioscience Co., Ltd. | Intrahepatic Cholangiocarcinoma | 05/27 | 05/27 | | |
NCT04521153: Camrelizumab Combined With Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma |
|
|
| Active, not recruiting | 2/3 | 294 | RoW | Camrelizumab, Apatinib Mesylate, TACE treatment, Radical surgery | Shanghai Zhongshan Hospital | Hepatocellular Carcinoma, Immunotherapy, Molecular Targeted Therapy | 07/25 | 03/26 | | |
zs-ICC-2019, NCT03951597: Combined Therapy Using Oxaliplatin and Gemcitabine Chemotherapy, Lenvatinib and PD1 Antibody (JS001) for Patients With Advanced and Unresectable Intrahepatic Cholangiocarcinoma |
|
|
| Active, not recruiting | 2 | 30 | RoW | combined therapy using oxaliplatin and gemcitabine chemotherapy, Lenvatinib and PD1 antibody (JS001) | Shanghai Zhongshan Hospital | Cholangiocarcinoma, Intrahepatic | 01/20 | 11/21 | | |
zs-ICC-2020, NCT04361331: Two-cohort Study of Toripalimab(PD1)+Lenvatnib, or Gemox+Lenvatinib in Advanced Intrahepatic Cholangiocarcinoma |
|
|
| Active, not recruiting | 2 | 60 | RoW | Lenvatinib combined with gemox, gemox chemotherapy, Toripalimab combined with lenvatinib | Shanghai Zhongshan Hospital | Cholangiocarcinoma, Intrahepatic | 09/21 | 12/21 | | |
NCT04961788: Anti-PD1 Antibody Toripalimab Combined With Gemox as First-line Therapy in Late-stage Intrahepatic Cholangiocarcinoma |
|
|
| Recruiting | 2 | 30 | RoW | Gemox combimed PD1 antibody | Shanghai Zhongshan Hospital | Intrahepatic Cholangiocarcinoma | 12/21 | 12/22 | | |
NCT04850157: Tislelizumab Combined With IMRT Neoadjuvant Treatment for Resectable Hepatocellular Carcinoma With PVTT |
|
|
| Not yet recruiting | 2 | 30 | RoW | Tislelizumab, IMRT | Shanghai Zhongshan Hospital | Hepatocellular Carcinoma With Portal Vein Tumor Thrombus | 04/22 | 12/23 | | |
NCT04295317: PD-1 Antibody (SHR-1210) Plus Capecitabine in Patients with Intrahepatic Cholangiocarcinoma After Surgery |
|
|
| Active, not recruiting | 2 | 65 | RoW | PD-1 blocking antibody SHR-1210, Capecitabine | Shanghai Zhongshan Hospital | Intrahepatic Cholangiocarcinoma | 06/25 | 06/25 | | |
NCT05262959: A Single Center Study of Donafenib Combined With PD-1 + TACE in the First-line Treatment of aHCC |
|
|
| Completed | 2 | 30 | RoW | Donafenib, PD-1, TACE | Shanghai Zhongshan Hospital | Donafenib | 04/24 | 05/24 | | |
NCT06530784: Cryoablation Combined With PD-1 Antibody and Bevacizumab for Hepatocellular Carcinoma |
|
|
| Not yet recruiting | 2 | 36 | RoW | Cryoablation, PD-1 antibody and bevacizumab | Shanghai Zhongshan Hospital | Carcinoma, Hepatocellular | 12/25 | 05/26 | | |
NCT06737081: SAL-0951 in the Treatment of Chemotherapy-induced Anemia in Patients With Non-myeloid Malignancies |
|
|
| Recruiting | 2 | 60 | RoW | SAL-0951 tablets 4mg, SAL-0951 tablets 4mg group, SAL-0951 tablets 5mg, SAL-0951 tablets 5mg group | Shenzhen Salubris Pharmaceuticals Co., Ltd. | Anemia | 12/25 | 06/26 | | |
NCT06778031: A Clinical Study of SHR-A1811 in the Treatment of HER2-positive Locally Advanced or Metastatic Biliary Tract Cancer |
|
|
| Not yet recruiting | 2 | 54 | RoW | SHR-A1811, SHR-1316, SHR-8068 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | HER2-positive Locally Advanced or Metastatic Biliary Tract Cancer | 06/28 | 09/28 | | |
| Recruiting | 1/2 | 30 | RoW | Toripalimab, Sorafenib | Shanghai Zhongshan Hospital | Hepatocellular Carcinoma | 10/21 | 12/21 | | |
NCT05652920: Ori-C101Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of HCC |
|
|
| Recruiting | 1/2 | 105 | RoW | Ori-C101 | OriCell Therapeutics Co., Ltd. | Hepatocellular Carcinoma | 12/26 | 12/26 | | |
NCT05627063: A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK121-NX in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 169 | US, RoW | ABSK121-NX | Abbisko Therapeutics Co, Ltd | Solid Tumor | 03/25 | 06/25 | | |
BIATICH, NCT05593380: The Effect of BIA Monitoring of Brain Edema on the Neurological Prognosis of Supratentorial Massive ICH |
|
|
| Recruiting | N/A | 190 | RoW | Parenchymal Intracranial pressure monitor, Integra Life Sciences Camino Intracranial Monitor, Treatment based on clinical and imaging observations | Xiangya Hospital of Central South University | Cerebral Hemorrhage, Hypertensive, Intracranial Hypertension, Monitoring, Critical Care, Treatment Outcome, Invasive Intracranial Pressure Monitoring, Large-volume Cerebral Hemorrhage | 12/24 | 03/25 | | |
NCT06178809: Clinical Research on Dynamic Monitoring MRD Via Plasma ctDNA After Systemic Therapy of Hepatocellular Carcinoma |
|
|
| Recruiting | N/A | 475 | RoW | | Singlera Genomics Inc., Shanghai Zhongshan Hospital | Hepatocellular Carcinoma | 04/25 | 12/25 | | |
NCT05200221: A Single Center Real-world Study of Donafenib in the Treatment of Hepatocellular Carcinoma in Routine Clinical Practice |
|
|
| Recruiting | N/A | 300 | RoW | | Shanghai Zhongshan Hospital | Donafenib, Hepatocellular Carcinoma | 01/24 | 03/24 | | |
NCT05941286: Effect of Continuous Glucose Monitoring System Alerts on Diabetes Management in the Hospital |
|
|
| Recruiting | N/A | 527 | RoW | CGM system with both glucose predictive alerts and threshold alerts on, CGM system with only glucose threshold alerts on, CGM system with glucose alerts off | Shanghai 6th People's Hospital | Diabetes Mellitus | 08/25 | 09/25 | | |
NCT06023147: A Real-world Study of the Short-term Efficacy and Safety of E-TACE in Patients With Hepatocellular Carcinoma (HCC) |
|
|
| Not yet recruiting | N/A | 298 | RoW | E-TACE | Xuhua Duan | Hepatocellular Carcinoma | 09/24 | 09/25 | | |
NCT06591286: Effects of Real-time Continuous Glucose Monitoring System on Hospital-to-home Transitional Blood Glucose Control |
|
|
| Recruiting | N/A | 150 | RoW | RT-CGM, SMBG | Shanghai 6th People's Hospital | Diabetes Mellitus, Type 2 | 03/26 | 09/27 | | |
NCT06662630: Physiological Effects and Safety of Continuous High-frequency Oscillatory Ventilation in Mechanical Ventilation Patients |
|
|
| Recruiting | N/A | 30 | RoW | High-Frequency Oscillatory Ventilation | Shanghai Zhongshan Hospital | Atelectasis, Acute Respiratory Distress Syndrome, VAP - Ventilator Associated Pneumonia | 10/25 | 10/26 | | |
NCT05087459: Treatment of Avatrombopag for Thrombocytopenia in Patients Undergoing Selective Resection of Hepatocellular Carcinoma |
|
|
| Recruiting | N/A | 141 | RoW | Avatrombopag, Doptelet | Shanghai Zhongshan Hospital | Thrombocytopenia | 06/22 | 07/22 | | |
NCT05431621: Establishment of Molecular Classification Models for Early Diagnosis of Digestive System Cancers |
|
|
| Completed | N/A | 2430 | RoW | | Shanghai Zhongshan Hospital, Xuhui Central Hospital, Shanghai, Changhai Hospital, Hubei Cancer Hospital, Shanghai Public Health Clinical Center, Singlera Genomics Inc. | Esophageal Cancer, Gastric (Stomach) Cancer, Colorectal Cancer, Hepatocellular Carcinoma | 06/23 | 07/23 | | |
NCT05707585: Lung Cancer Diagnosis by Detecting Epigenetic Imprinting Alterations in Bronchoalveolar Lavage |
|
|
| Recruiting | N/A | 2064 | RoW | Quantitative Chromogenic Imprinted Gene in situ Hybridization (QCIGISH) | The Second Affiliated Hospital of Dalian Medical University, Fudan University, Zongda Hospital affiliated to Southeast University, West China Hospital, Henan Provincial People's Hospital, First Hospital of China Medical University, Shengjing Hospital, The First Affiliated Hospital of Guangzhou Medical University, Lisen Imprinting Diagnostics, Inc. | Lung Cancer | 01/24 | 07/24 | | |
| Ren, Zhenggang |
NCT01936233: Clinical Study of Antiviral and Aspirin Treatment in Liver Cancer After Radical Surgery |
|
|
| Recruiting | 3 | 112 | RoW | Aspirin, Lamivudine | Fudan University | Hepatocellular Carcinoma, Recurrence | 12/21 | 12/23 | | |
ALTN-AK105-III-02, NCT04344158: A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC) |
|
|
| Active, not recruiting | 3 | 648 | RoW | AK105 Injection, Anlotinib Hydrochloride Capsules, Sorafenib Tosylate Tablets | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Hepatocellular Carcinoma (HCC) | 12/26 | 12/26 | | |
NCT05823285: A Study Evaluates the Safety, Pharmacokinetics, Immunogenicity and Efficacy of QLS31903 in Advanced Solid Tumor Patients |
|
|
| Recruiting | 1 | 150 | RoW | QLS31903 | Qilu Pharmaceutical Co., Ltd. | Advanced Solid Tumors | 06/25 | 06/27 | | |
NCT04520906: To Evaluate the Safety and Efficacy of Microwave Ablation Therapy in Patients With Primary Liver Cancer |
|
|
| Recruiting | N/A | 139 | RoW | microwave ablation | Suzhou Hengruihongyuan Medical Technology Co. LTD | Hepatocellular Carcinoma | 01/23 | 12/23 | | |
